目的 探討芩香清解口服液聯(lián)合磷酸奧司他韋顆粒治療兒童上呼吸道感染的臨床療效。方法 選取哈爾濱醫(yī)科大學(xué)附屬第六醫(yī)院2021年6月—2022年6月收治的124例上呼吸道感染患兒，采用隨機(jī)數(shù)字表法將所有患兒分為對(duì)照組（62例）和治療組（62例）。對(duì)照組患兒口服磷酸奧司他韋顆粒，2次/d，體質(zhì)量≤15 kg，30 mg/次；23 kg≥體質(zhì)量＞15 kg，45 mg/次；40 kg≥體質(zhì)量＞23 kg，60 mg/次；體質(zhì)量＞40 kg，75 mg/次。治療組在對(duì)照組基礎(chǔ)上口服芩香清解口服液，3歲≤患兒年齡＜7歲，10 mL/次；7歲≤患兒年齡＜14歲，15 mL/次；3次/d。兩組均治療1周。比較兩組的臨床療效、臨床癥狀、炎癥因子。結(jié)果 治療后，治療組的總有效率為91.94%，高于對(duì)照組的總有效率79.03%（P＜0.05）。與對(duì)照組相比，治療組的咽喉腫痛、發(fā)熱、流鼻涕、肺啰音、咳嗽、乏力消失時(shí)間更短（P＜0.05）。治療后，兩組患兒血清C反應(yīng)蛋白（CRP）、白細(xì)胞介素-1β（IL-1β）、可溶性白細(xì)胞介素-2受體（SIL-2R）、淀粉樣蛋白A（SAA）水平下降，γ干擾素（IFN-γ）水平升高（P＜0.05）。與對(duì)照組相比，治療組血清CRP、IL-1β、SIL-2R、SAA水平更低，IFN-γ水平更高（P＜0.05）。結(jié)論 芩香清解口服液聯(lián)合磷酸奧司他韋顆?？捎糜谥委焹和虾粑栏腥荆岣邫C(jī)體免疫力，改善患兒血清炎癥因子水平。

Objective To explore the clinical efficacy of Qinxiang Qingjie Oral Liquid combined with Oseltamivir Phosphate Granules in treatment of upper respiratory tract infections in children. Methods Children (124 cases) with upper respiratory tract infections in Jiangnan Campus of the Sixth Affiliated Hospital of Harbin Medical University from June 2021 to June 2022 were divided into the control group (62 cases) and the treatment group (62 cases) using the random number table method. Children in the control group were po administered with Oseltamivir Phosphate Granules, weight ≤ 15 kg, 30 mg; 23 kg ≥ weight >15 kg, 45 mg; 40 kg ≥ weight > 23 kg, 60 mg; weight > 40 kg, 75 mg; twice daily. Children in the treatment group were po administered with Qinxiang Qingjie Oral Liquid on the basis of the control group, 3 — 7 years old, 10 mL/time; 7 — 14 years old, 15 mL/time; three times daily. Children in two groups were treated for 1 week. The clinical efficacies, the clinical symptoms, and inflammatory factor indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group was 91.94%, which was higher than 79.03% of the control group (P < 0.05). Compared with the control group, the disappearance time of sore throat, fever, runny nose, lung rales, cough, and fatigue in the treatment group was shorter (P< 0.05). After treatment, the serum levels of CRP, IL-1β, SIL-2R, and SAA in two groups were decreased, but the serum levels of IFN-γ in two groups were increased (P < 0.05). Compared with the control group, the levels of CRP, IL-1β, SIL-2R, and SAA in the treatment group were lower, but the levels of IFN-γ were higher (P < 0.05). Conclusion Qinxiang Qingjie Oral Liquid combined with Oseltamivir Phosphate Granules can be used to treat upper respiratory tract infections in children, improve the body’s immunity, and improve the serum inflammatory factor levels in children.

R974;R985

黑龍江省自然科學(xué)基金資助項(xiàng)目（A20200451）